5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bottlebrush-architectured poly(ethylene glycol) as an efficient vector for RNA interference in vivo

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bottlebrush-structured PEG substantially enhances the pharmacokinetics of conjugated siRNA and RNAi activity in vivo.

          Abstract

          Nonhepatic delivery of small interfering RNAs (siRNAs) remains a challenge for development of RNA interference–based therapeutics. We report a noncationic vector wherein linear poly(ethylene glycol) (PEG), a polymer generally considered as inert and safe biologically but ineffective as a vector, is transformed into a bottlebrush architecture. This topology provides covalently embedded siRNA with augmented nuclease stability and cellular uptake. Consisting almost entirely of PEG and siRNA, the conjugates exhibit a ~25-fold increase in blood elimination half-life and a ~19-fold increase in the area under the curve compared with unmodified siRNA. The improved pharmacokinetics results in greater tumor uptake and diminished liver capture. Despite the structural simplicity these conjugates efficiently knock down target genes in vivo without apparent toxic and immunogenic reactions. Given the benign biological nature of PEG and its widespread precedence in biopharmaceuticals, we anticipate the brush polymer–based technology to have a significant impact on siRNA therapeutics.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Knocking down barriers: advances in siRNA delivery

          Key Points RNA interference (RNAi) is a fundamental pathway in eukaryotic cells by which sequence-specific small interfering RNA (siRNA) is able to silence genes through the destruction of complementary mRNA. RNAi is an important therapeutic tool that can be used to silence aberrant endogenous genes or to knockdown genes essential to the proliferation of infectious organisms. Delivery remains the central challenge to the therapeutic application of RNAi technology. Before siRNA can take effect in the cytoplasm of a target cell, it must be transported through the body to the target site without undergoing clearance or degradation. Currently, the most effective synthetic, non-viral delivery agents of siRNA are lipids, lipid-like materials and polymers. Various cationic agents including stable nucleic acid–lipid particles, lipidoids, cyclodextrin polymers and polyethyleneimine polymers have been used to achieve the successful systemic delivery of siRNA in mammals without inducing significant toxicity. Direct conjugation of delivery agents to siRNA can facilitate delivery. For example, cholesterol-modified siRNA enables targeting to the liver. RNAi therapeutics have progressed to the clinic, where studies are being conducted to determine siRNA efficacy in treating several diseases, including age-related macular degeneration and respiratory syncytial virus. Moving forward, it will be important to pay close attention to the potential nonspecific immunostimulatory effects of siRNA. Modifications to siRNA can be used to minimize stimulation of the immune system, and an increased emphasis must be placed on performing proper controls to ensure that therapeutic effects are sequence-specific.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Overcoming cellular barriers for RNA therapeutics

            Recent progress in delivering RNA therapeutics to the inside of cells might lead to more success in clinical applications.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The promises and pitfalls of RNA-interference-based therapeutics.

              The discovery that gene expression can be controlled by the Watson-Crick base-pairing of small RNAs with messenger RNAs containing complementary sequence - a process known as RNA interference - has markedly advanced our understanding of eukaryotic gene regulation and function. The ability of short RNA sequences to modulate gene expression has provided a powerful tool with which to study gene function and is set to revolutionize the treatment of disease. Remarkably, despite being just one decade from its discovery, the phenomenon is already being used therapeutically in human clinical trials, and biotechnology companies that focus on RNA-interference-based therapeutics are already publicly traded.
                Bookmark

                Author and article information

                Journal
                Sci Adv
                Sci Adv
                SciAdv
                advances
                Science Advances
                American Association for the Advancement of Science
                2375-2548
                February 2019
                20 February 2019
                : 5
                : 2
                : eaav9322
                Affiliations
                [1 ]Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
                [2 ]David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
                Author notes
                [* ]Corresponding author. Email: xueguang@ 123456mit.edu (X.L.); k.zhang@ 123456northeastern.edu (K.Z.)
                Author information
                http://orcid.org/0000-0002-0923-0027
                http://orcid.org/0000-0001-7779-0424
                http://orcid.org/0000-0002-2754-6009
                http://orcid.org/0000-0002-0218-5147
                http://orcid.org/0000-0003-1652-0759
                http://orcid.org/0000-0002-6423-3618
                http://orcid.org/0000-0002-1069-7265
                http://orcid.org/0000-0002-8142-6702
                Article
                aav9322
                10.1126/sciadv.aav9322
                6382396
                30801019
                6e734300-f983-497d-b242-1e917838c8c5
                Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

                This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 02 November 2018
                : 11 January 2019
                Funding
                Funded by: doi http://dx.doi.org/10.13039/100000001, National Science Foundation;
                Award ID: National Science Foundation
                Funded by: doi http://dx.doi.org/10.13039/100000057, National Institute of General Medical Sciences;
                Award ID: 1R01GM121612-01
                Categories
                Research Article
                Research Articles
                SciAdv r-articles
                Chemistry
                Health and Medicine
                Molecular Biology
                Custom metadata
                Meann Ramirez

                Comments

                Comment on this article